On 30 July 2026, the Pharmaceutical Benefits Advisory Committee (PBAC) held a special out-of-session meeting to consider a request to amend the existing PBS listing for triptorelin 3.75 mg intramuscular injection to support its use across a number of women's health conditions.
The outcomes from this special out-of-session meeting are now available on the PBS website.